Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.Â
GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma.Â
Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.Â
Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.Â
IMUNON Inc. announced additional clinical data from ongoing analyses of results from the company’s phase II OVATION 2 Study of IMNN-001, its investigational interleukin-12 immunotherapy for the treatment of advanced ovarian cancer based on its proprietary TheraPlas technology.Â
A study in women with breast cancer suggests that low oral doses of minoxidil, taken during or after cancer treatment, appear to regrow hair in most patients and without causing any serious heart-related side effects that require additional therapies or hospitalization.
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer.
